Kiora Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Kiora PharmaceuticalsSe prevé que los beneficios de la empresa disminuyan en 0.7% al año, mientras que sus ingresos anuales crecerán en 47.4% al año. Se espera que el BPA de grow sea de 58% al año.

Información clave

-6.1%

Tasa de crecimiento de los beneficios

66.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	20.3%
Tasa de crecimiento de los ingresos	25.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:KPRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-19	N/A	N/A	2
12/31/2025	2	-15	N/A	N/A	2
12/31/2024	12	-1	N/A	N/A	3
12/31/2023	N/A	-13	-10	-10	N/A
9/30/2023	N/A	-13	-9	-9	N/A
6/30/2023	N/A	-12	-10	-10	N/A
3/31/2023	N/A	-12	-11	-11	N/A
12/31/2022	N/A	-14	-10	-10	N/A
9/30/2022	N/A	-17	-11	-11	N/A
6/30/2022	N/A	-15	-11	-11	N/A
3/31/2022	N/A	-15	-11	-11	N/A
12/31/2021	N/A	-14	-11	-11	N/A
9/30/2021	0	-9	-10	-9	N/A
6/30/2021	0	-8	-9	-9	N/A
3/31/2021	0	-7	-8	-7	N/A
12/31/2020	0	-7	-7	-7	N/A
9/30/2020	N/A	-8	-8	-8	N/A
6/30/2020	N/A	-10	-8	-8	N/A
3/31/2020	N/A	-10	-8	-8	N/A
12/31/2019	3	-7	-8	-8	N/A
9/30/2019	3	-7	-8	-8	N/A
6/30/2019	3	-7	-9	-8	N/A
3/31/2019	3	-8	-9	-9	N/A
12/31/2018	2	-11	-11	-11	N/A
9/30/2018	2	-11	-11	-10	N/A
6/30/2018	1	-12	-10	-10	N/A
3/31/2018	1	-13	-11	-11	N/A
12/31/2017	0	-13	-7	-6	N/A
9/30/2017	1	-14	N/A	-7	N/A
6/30/2017	1	-13	N/A	-7	N/A
3/31/2017	1	-14	N/A	-7	N/A
12/31/2016	1	-13	N/A	-8	N/A
9/30/2016	1	-12	N/A	-8	N/A
6/30/2016	0	-10	N/A	-6	N/A
3/31/2016	N/A	-8	N/A	-4	N/A
12/31/2015	N/A	-17	N/A	-4	N/A
9/30/2015	N/A	-14	N/A	-3	N/A
6/30/2015	N/A	-13	N/A	-3	N/A
3/31/2015	N/A	-12	N/A	-2	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-3	N/A	-2	N/A
3/31/2014	N/A	-4	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: KPRX se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: KPRX se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: KPRX se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: KPRXSe prevé que los ingresos de la empresa (25.9% al año) crezcan más deprisa que los del mercado US (8.2% al año).

Ingresos de alto crecimiento: KPRXSe prevé que los ingresos de la empresa (25.9% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de KPRX se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Kiora Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 69% to US$3.83

Price target increased by 42% to US$17.50

Price target decreased by 56% to US$20.00

Price target increased by 39% to US$65.50

No longer forecast to breakeven

Price target decreased to US$11.83

Recent updates

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

New major risk - Revenue and earnings growth

Price target decreased by 69% to US$3.83

New major risk - Share price stability

Price target increased by 42% to US$17.50

Kiora Pharmaceuticals, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Price target decreased by 56% to US$20.00

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target increased by 39% to US$65.50

Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301

Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

High number of new directors

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

High number of new directors

Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022

Kiora Pharmaceuticals reports 1H results

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. Appoints Susan L. Drexler as Interim Chief Financial Officer

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer

Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022

Kiora Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Price target decreased to US$11.83

EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.

Director Steven Boyd has left the company

Director I. Maher has left the company

EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study

No longer forecast to breakeven

Price target decreased to US$13.08

Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)

New 90-day high: US$7.30

EyeGate Pharmaceuticals, Inc. Announces Board Appointments

New 90-day high: US$6.63

EyeGate Pharmaceuticals announces $8M private placement

Price target raised to US$12.83

EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million.

New 90-day high: US$5.21

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Earnings beat expectations

New 90-day low: US$3.57

Price target lowered to US$11.17

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento